Evaluation of clinicopathological factors and the correlation between the adhesion molecule CD44 variant 9 expression and pulmonary metastases from colorectal cancers.
Pulmonary metastases occur in 3% to 8% of all cases of colorectal cancers. Therefore, we evaluated prognostic factors and examined the correlation between the expression of adhesion molecule CD44 variant 9 and the pulmonary metastasis from colorectal cancer. Of 512 patients with colorectal cancers, clinicopathological findings, prognoses, and prognostic factors were evaluated in 42 patients with pulmonary metastases (8%), together with the expression of adhesion molecule CD44 variant 9 by immunohistochemical staining with monoclonal antibody prepared in our department. It was found that the presence or absence of extrapulmonary metastasis, treatment by pulmonary resection, and serum carcinoembryonic antigen levels were prognostic factors. The 5-year survival rate was 35% in patients who underwent pulmonary resection. In addition, adhesion molecule CD44 variant 9 was expressed in the primary colorectal cancers in 89 (42%) of 213 patients without hematogenous metastases and 23 (88%) of 26 patients with pulmonary metastases. Therefore, the rate of CD44 variant 9 expression in the primary colorectal cancer tissues was significantly higher in patients with pulmonary metastases from colorectal cancers. Among patients with pulmonary metastases from colorectal cancers, long-term survival was achieved in those without extrapulmonary metastases, because metastatic tumors in the lungs were completely removed by pulmonary resection. In addition, the abnormal expression of adhesion molecule CD44 variant 9 in the primary colorectal cancer is partly responsible for pulmonary metastasis.